CELUHealthcare · BiotechnologyCELU Stock Forecast: Celularity, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 21 Aug 2026 — in the weakest quartile.
CELU stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Celularity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
CELU stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CELU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2025 | WBB Securities | Upgrade | Buy | — |
| 9 Sept 2025 | WBB Securities | Upgrade | Buy | $6.00 |
| 18 Aug 2025 | WBB Securities | Initiates | Speculative Buy | — |
| 30 Jan 2023 | HC Wainwright & Co. | Maintains | Buy | $15 → $2.50 |
| 30 Jan 2023 | Morgan Stanley | Downgrade | Underweight | $5.00 → $1.00 |
| 22 Dec 2022 | Oppenheimer | Downgrade | Perform | — |
| 12 Sept 2022 | Morgan Stanley | Maintains | Equal-Weight | $8.00 → $5.00 |
| 25 Aug 2022 | Alliance Global Partners | Initiates | Buy | $15 |
| 23 Aug 2022 | Truist Securities | Maintains | Hold | $10 → $6.00 |
| 22 June 2022 | HC Wainwright & Co. | Initiates | Buy | — |
| 6 Apr 2022 | Truist Securities | Downgrade | Hold | — |
| 28 Jan 2022 | Oppenheimer | Initiates | Outperform | — |
| 24 Nov 2021 | Morgan Stanley | Initiates | Equal-Weight | — |
| 19 Oct 2021 | Truist Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELU appears on the weeks it earns a place.
CELU analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Celularity, Inc. (CELU) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 2.3×
- Price / sales
- 0.9×
- Price / book
- —
- EV / EBITDA
- −1.7×
Cheaper than 69% of US stocks
Cheaper than 73% of US stocks
Cheaper than 70% of US stocks
- Revenue growth (YoY)
- −77.4%
- Earnings growth (YoY)
- −77.4%
- Gross margin
- −79.7%
- Operating margin
- −492.2%
- Net margin
- 24.4%
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 2% of US stocks
Higher than 8% of US stocks
Higher than 85% of US stocks
- Return on equity
- 241.2%
- Return on assets
- −30.9%
- Dividend yield
- —
Higher than 98% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CELU vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Celularity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about CELU stock
How does Ticker Nerd's model rank CELU?
As at 21 Aug 2026, Celularity, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
What is the CELU stock forecast for 2030?
No analyst covering Celularity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELU are extrapolating price history, which says nothing about the business.
How has CELU stock performed over the past year?
Celularity, Inc. returned -77.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Celularity, Inc. do?
Celularity Inc. is a biotechnology company that specializes in developing off-the-shelf placental-derived allogeneic cell therapies for cancer and other serious diseases.
About Celularity, Inc.
Celularity Inc. is a biotechnology company that specializes in developing off-the-shelf placental-derived allogeneic cell therapies for cancer and other serious diseases. The primary focus of the company is to harness the unique properties of postpartum placental cells to create advanced cellular therapies. These innovative solutions aim to address unmet medical needs in immuno-oncology, infectious diseases, and degenerative diseases. Celularity Inc. leverages its proprietary technology platform to produce these cellular products, which are designed to enhance immune responses and offer therapeutic benefits. The company's work significantly impacts the healthcare and biotechnology sectors, where there is a continuous demand for transformative treatments that can improve patient outcomes. Situated at the forefront of cell therapy development, Celularity Inc. plays a pivotal role in advancing the understanding and application of cellular medicine, making its contributions highly valuable within the financial markets and the broader biopharmaceutical landscape.
CEO Dr. Robert Joseph Hariri M.D., Ph.D. · 115 employees · United States · https://www.celularity.com